• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Leukocytosis is linked to thrombosis at diagnosis, while JAK2 V617F mutation is associated with thrombosis during the course of essential thrombocythemia.

作者信息

Ohyashiki Kazuma, Kiguchi Toru, Ito Yoshikazu, Fujimoto Hiroaki, Gotoh Akihiko, Tauchi Tetsuzo, Miyazawa Keisuke, Kimura Yukihiko, Ohyashiki Junko H

机构信息

Hematology Division, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo, 169-0023, Japan.

Intractable Immune System Diseases Research Center, Tokyo Medical University, Tokyo, Japan.

出版信息

Int J Hematol. 2008 May;87(4):446-448. doi: 10.1007/s12185-008-0080-9.

DOI:10.1007/s12185-008-0080-9
PMID:18409076
Abstract
摘要

相似文献

1
Leukocytosis is linked to thrombosis at diagnosis, while JAK2 V617F mutation is associated with thrombosis during the course of essential thrombocythemia.白细胞增多症与诊断时的血栓形成有关，而JAK2 V617F突变与原发性血小板增多症病程中的血栓形成有关。
Int J Hematol. 2008 May;87(4):446-448. doi: 10.1007/s12185-008-0080-9.
2
Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain.JAK2 V617F对原发性血小板增多症患者血栓形成风险的影响：衡量不确定性。
Haematologica. 2008 Sep;93(9):1412-4. doi: 10.3324/haematol.12970. Epub 2008 Jul 18.
3
Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status.白细胞增多是原发性血小板增多症中血栓形成的一个危险因素：与治疗、标准危险因素及Jak2突变状态的相互作用。
Blood. 2007 Mar 15;109(6):2310-3. doi: 10.1182/blood-2006-09-046342. Epub 2006 Nov 16.
4
Reemergence of JAK2 V617F clone heralds extramedullary leukemia relapse after BMT for transformed essential thrombocytosis.JAK2 V617F克隆的再次出现预示着转化型原发性血小板增多症在进行异基因骨髓移植后髓外白血病复发。
Ann Hematol. 2007 Feb;86(2):145-7. doi: 10.1007/s00277-006-0213-2. Epub 2006 Nov 17.
5
Clinical relevance of JAK2 (V617F) mutant allele burden.JAK2（V617F）突变等位基因负荷的临床相关性。
Haematologica. 2009 Jan;94(1):7-10. doi: 10.3324/haematol.2008.001271.
6
JAK2 V617F: implications for thrombosis in myeloproliferative diseases.JAK2 V617F：对骨髓增殖性疾病中血栓形成的影响
Curr Opin Hematol. 2007 Sep;14(5):450-4. doi: 10.1097/MOH.0b013e3282861d1b.
7
JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients.真性红细胞增多症中JAK2 V617F突变：275例患者队列中与临床特征、治疗反应及长期预后的相关性
Leuk Lymphoma. 2009 Feb;50(2):247-53. doi: 10.1080/10428190802688152.
8
The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia.真性红细胞增多症中白细胞增多与其他血栓形成危险因素之间的相互作用。
Blood. 2007 May 1;109(9):4105. doi: 10.1182/blood-2007-01-066985.
9
Leukocytosis and risk stratification assessment in essential thrombocythemia.原发性血小板增多症中的白细胞增多及风险分层评估
J Clin Oncol. 2008 Jun 1;26(16):2732-6. doi: 10.1200/JCO.2007.15.3569. Epub 2008 Apr 28.
10
The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia.真性红细胞增多症中JAK2V617F突变及白细胞增多与血栓形成事件的关联
Exp Hematol. 2007 Nov;35(11):1704-7. doi: 10.1016/j.exphem.2007.08.011. Epub 2007 Oct 17.

引用本文的文献

1
Molecular Genetics of Thrombotic Myeloproliferative Neoplasms: Implications in Precision Oncology.血栓性骨髓增殖性肿瘤的分子遗传学：对精准肿瘤学的启示
Diagnostics (Basel). 2023 Jan 3;13(1):163. doi: 10.3390/diagnostics13010163.
2
Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis.原发性血小板增多症和真性红细胞增多症中的白细胞增多和血栓形成：系统评价和荟萃分析。
Blood Adv. 2019 Jun 11;3(11):1729-1737. doi: 10.1182/bloodadvances.2019000211.
3
Emergence of chronic myelogenous leukemia during treatment for essential thrombocythemia.

本文引用的文献

1
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.世界卫生组织真性红细胞增多症、原发性血小板增多症和原发性骨髓纤维化诊断标准修订提案及理由：一个特设国际专家小组的建议
Blood. 2007 Aug 15;110(4):1092-7. doi: 10.1182/blood-2007-04-083501. Epub 2007 May 8.
2
Thrombosis can occur at any phase of essential thrombocythemia with JAK2(V617F) mutation: a single institutional study in Japan.在伴有JAK2（V617F）突变的原发性血小板增多症的任何阶段都可能发生血栓形成：日本一项单中心研究
Leukemia. 2007 Jul;21(7):1570-1. doi: 10.1038/sj.leu.2404666. Epub 2007 Mar 29.
3
原发性骨髓纤维化中出现慢性髓性白血病。
Int J Hematol. 2010 Apr;91(3):516-21. doi: 10.1007/s12185-010-0502-3. Epub 2010 Feb 11.
4
Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results.采用评分系统决策启动原发性血小板增多症患者的血小板降低治疗：长期结果。
Int J Hematol. 2009 Nov;90(4):486-491. doi: 10.1007/s12185-009-0401-7. Epub 2009 Aug 22.
5
Novel strategies for patients with chronic myeloproliferative disorders.慢性骨髓增殖性疾病患者的新策略。
Curr Opin Hematol. 2009 Mar;16(2):129-34. doi: 10.1097/MOH.0b013e3283257a9e.
6
Comparison of clinicopathologic findings according to JAK2 V617F mutation in patients with essential thrombocythemia.原发性血小板增多症患者中根据JAK2 V617F突变的临床病理结果比较
Int J Hematol. 2009 Jan;89(1):39-44. doi: 10.1007/s12185-008-0222-0. Epub 2008 Dec 18.
WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.
世界卫生组织（WHO）骨髓特征及欧洲临床、分子和病理（ECMP）诊断骨髓增殖性疾病标准。
Leuk Res. 2007 Aug;31(8):1031-8. doi: 10.1016/j.leukres.2007.01.021. Epub 2007 Mar 23.
4
JAK2(V617F) mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders.
Leukemia. 2007 May;21(5):1097-9. doi: 10.1038/sj.leu.2404604. Epub 2007 Feb 22.
5
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.真性红细胞增多症和特发性红细胞增多症中的JAK2外显子12突变
N Engl J Med. 2007 Feb 1;356(5):459-68. doi: 10.1056/NEJMoa065202.
6
Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status.根据JAK2 V617F突变状态，原发性血小板增多症和真性红细胞增多症患者的血栓形成风险。
Haematologica. 2007 Jan;92(1):135-6. doi: 10.3324/haematol.10634.
7
Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status.白细胞增多是原发性血小板增多症中血栓形成的一个危险因素：与治疗、标准危险因素及Jak2突变状态的相互作用。
Blood. 2007 Mar 15;109(6):2310-3. doi: 10.1182/blood-2006-09-046342. Epub 2006 Nov 16.
8
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.基于JAK2 V617F突变状态的原发性血小板增多症亚型定义及其与真性红细胞增多症的关系：一项前瞻性研究。
Lancet. 2005 Dec 3;366(9501):1945-53. doi: 10.1016/S0140-6736(05)67785-9.
9
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.一种导致持续性信号传导的独特克隆性JAK2突变会引发真性红细胞增多症。
Nature. 2005 Apr 28;434(7037):1144-8. doi: 10.1038/nature03546.